Benchmark Reiterates Buy on Surgery Partners, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bill Sutherland has reiterated a 'Buy' rating on Surgery Partners (NASDAQ:SGRY) and maintained a price target of $50.
August 04, 2023 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst has reiterated a 'Buy' rating on Surgery Partners and maintained a price target of $50.
The reiteration of a 'Buy' rating by a Benchmark analyst and the maintenance of a $50 price target indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100